-
1
-
-
84887319657
-
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms
-
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10, 627-636, https://doi.org/10.1038/nrgastro.2013.149 (2013).
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, pp. 627-636
-
-
Wree, A.1
Broderick, L.2
Canbay, A.3
Hoffman, H.M.4
Feldstein, A.E.5
-
2
-
-
84878930738
-
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
-
Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10, 330-344, https://doi.org/10.1038/nrgastro.2013.41 (2013).
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, pp. 330-344
-
-
Anstee, Q.M.1
Targher, G.2
Day, C.P.3
-
3
-
-
84864390922
-
The epidemiology, pathogenesis and histopathology of fatty liver disease
-
Levene, A. P. & Goldin, R. D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141-152, https://doi.org/10.1111/j.1365-2559.2011.04145.x (2012).
-
(2012)
Histopathology
, vol.61
, pp. 141-152
-
-
Levene, A.P.1
Goldin, R.D.2
-
4
-
-
0042165989
-
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
-
Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 (2003).
-
(2003)
Gastroenterology
, vol.125
, pp. 437-443
-
-
Feldstein, A.E.1
-
5
-
-
84861543083
-
The diagnosis and management of non-Alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
-
Chalasani, N. et al. The diagnosis and management of non-Alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005-2023, https://doi.org/10.1002/hep.25762 (2012).
-
(2012)
Hepatology
, vol.55
, pp. 2005-2023
-
-
Chalasani, N.1
-
6
-
-
0029046931
-
Identification of a nuclear receptor that is activated by farnesol metabolites
-
Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693 (1995).
-
(1995)
Cell
, vol.81
, pp. 687-693
-
-
Forman, B.M.1
-
7
-
-
1542513682
-
Expression and activation of the farnesoid X receptor in the vasculature
-
Bishop-Bailey, D., Walsh, D. T. & Warner, T. D. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 101, 3668-3673, https://doi.org/10.1073/pnas.0400046101 (2004).
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 3668-3673
-
-
Bishop-Bailey, D.1
Walsh, D.T.2
Warner, T.D.3
-
8
-
-
0034664729
-
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
-
Sinal, C. J. et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis. Cell 102, 731-744, https://doi.org/10.1016/S0092-8674(00)00062-3 (2000).
-
(2000)
Cell
, vol.102
, pp. 731-744
-
-
Sinal, C.J.1
-
9
-
-
67649210759
-
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-Alcoholic steatohepatitis
-
Zhang, S., Wang, J., Liu, Q. & Harnish, D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-Alcoholic steatohepatitis. J Hepatol 51, 380-388, https://doi.org/10.1016/j.jhep.2009.03.025 (2009).
-
(2009)
J Hepatol
, vol.51
, pp. 380-388
-
-
Zhang, S.1
Wang, J.2
Liu, Q.3
Harnish, D.C.4
-
10
-
-
84877916062
-
Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH
-
Bjursell, M. et al. Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 8, e64721, https://doi.org/10.1371/journal.pone.0064721 (2013).
-
(2013)
PLoS One
, vol.8
, pp. e64721
-
-
Bjursell, M.1
-
11
-
-
0037101810
-
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
-
Pellicciari, R. et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45, 3569-3572 (2002).
-
(2002)
J Med Chem
, vol.45
, pp. 3569-3572
-
-
Pellicciari, R.1
-
12
-
-
84996521986
-
Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice
-
Haczeyni, F. et al. Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity 25, 155-165, https://doi.org/10.1002/oby.21701 (2017).
-
(2017)
Obesity
, vol.25
, pp. 155-165
-
-
Haczeyni, F.1
-
13
-
-
85021683795
-
Farnesoid X receptor induces Takeda G-protein receptor 5 cross-Talk to regulate bile acid synthesis and hepatic metabolism
-
Pathak, P. et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-Talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem 292, 11055-11069, https://doi.org/10.1074/jbc.M117.784322 (2017).
-
(2017)
J Biol Chem
, vol.292
, pp. 11055-11069
-
-
Pathak, P.1
-
14
-
-
77950613528
-
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
-
Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 51, 771-784, https://doi.org/10.1194/jlr.M001602 (2010).
-
(2010)
J Lipid Res
, vol.51
, pp. 771-784
-
-
Cipriani, S.1
Mencarelli, A.2
Palladino, G.3
Fiorucci, S.4
-
15
-
-
85017474560
-
MiR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
-
e2748 10.1038/cddis.2017.172 28406477 5477590
-
Rodrigues, P. M. et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis 8, e2748, https://doi.org/10.1038/cddis.2017.172 (2017).
-
(2017)
Cell Death Dis
, vol.8
-
-
Rodrigues, P.M.1
-
16
-
-
22944449688
-
A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis
-
Fiorucci, S. et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314, 584-595, https://doi.org/10.1124/jpet.105.084905 (2005).
-
(2005)
J Pharmacol Exp Ther
, vol.314
, pp. 584-595
-
-
Fiorucci, S.1
-
17
-
-
84988001263
-
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
-
Verbeke, L. et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 6, 33453, https://doi.org/10.1038/srep33453 (2016).
-
(2016)
Sci Rep
, vol.6
-
-
Verbeke, L.1
-
18
-
-
7644244675
-
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
-
Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512 (2004).
-
(2004)
Gastroenterology
, vol.127
, pp. 1497-1512
-
-
Fiorucci, S.1
-
19
-
-
84880664792
-
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
-
Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582.e571, https://doi.org/10.1053/j.gastro.2013.05.042 (2013).
-
(2013)
Gastroenterology
, vol.145
, pp. 574-582
-
-
Mudaliar, S.1
-
20
-
-
84929266699
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
-
Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965, https://doi.org/10.1016/S0140-6736(14)61933-4 (2015).
-
(2015)
Lancet
, vol.385
, pp. 956-965
-
-
Neuschwander-Tetri, B.A.1
-
21
-
-
84982102773
-
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
-
Nevens, F. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 375, 631-643, https://doi.org/10.1056/NEJMoa1509840 (2016).
-
(2016)
N Engl J Med
, vol.375
, pp. 631-643
-
-
Nevens, F.1
-
22
-
-
80055004124
-
Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis
-
Itoh, M. et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 179, 2454-2463, https://doi.org/10.1016/j.ajpath.2011.07.014 (2011).
-
(2011)
Am J Pathol
, vol.179
, pp. 2454-2463
-
-
Itoh, M.1
-
23
-
-
27544450765
-
Divergence of melanocortin pathways in the control of food intake and energy expenditure
-
Balthasar, N. et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123, 493-505, https://doi.org/10.1016/j.cell.2005.08.035 (2005).
-
(2005)
Cell
, vol.123
, pp. 493-505
-
-
Balthasar, N.1
-
24
-
-
84892425701
-
Hepatic crown-like structure: A unique histological feature in non-Alcoholic steatohepatitis in mice and humans
-
Itoh, M. et al. Hepatic crown-like structure: A unique histological feature in non-Alcoholic steatohepatitis in mice and humans. PLoS One 8, e82163, https://doi.org/10.1371/journal.pone.0082163 (2013).
-
(2013)
PLoS One
, vol.8
, pp. e82163
-
-
Itoh, M.1
-
25
-
-
85015282883
-
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
-
Komiya, C. et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep 7, 44754, https://doi.org/10.1038/srep44754 (2017).
-
(2017)
Sci Rep
, vol.7
-
-
Komiya, C.1
-
26
-
-
84926351030
-
Eicosapentaenoic acid ameliorates non-Alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice
-
Konuma, K. et al. Eicosapentaenoic acid ameliorates non-Alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One 10, e0121528, https://doi.org/10.1371/journal.pone.0121528 (2015).
-
(2015)
PLoS One
, vol.10
, pp. e0121528
-
-
Konuma, K.1
-
27
-
-
84956731915
-
Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining
-
Yoshimura, K. et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 63, 462-473, https://doi.org/10.1002/hep.28226 (2016).
-
(2016)
Hepatology
, vol.63
, pp. 462-473
-
-
Yoshimura, K.1
-
28
-
-
84871221881
-
MiR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-Alcoholic fatty liver disease
-
Castro, R. E. et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-Alcoholic fatty liver disease. J Hepatol 58, 119-125, https://doi.org/10.1016/j.jhep.2012.08.008 (2013).
-
(2013)
J Hepatol
, vol.58
, pp. 119-125
-
-
Castro, R.E.1
-
29
-
-
84880925312
-
Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-Alcoholic fatty liver disease
-
Derdak, Z. et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-Alcoholic fatty liver disease. J Hepatol 58, 785-791, https://doi.org/10.1016/j.jhep.2012.11.042 (2013).
-
(2013)
J Hepatol
, vol.58
, pp. 785-791
-
-
Derdak, Z.1
-
30
-
-
79961010787
-
Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice
-
Kodama, T. et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 121, 3343-3356, https://doi.org/10.1172/jci44957 (2011).
-
(2011)
J Clin Invest
, vol.121
, pp. 3343-3356
-
-
Kodama, T.1
-
31
-
-
85046423533
-
CD11c+ resident macrophages drive hepatocyte death-Triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis
-
Itoh, M. et al. CD11c+ resident macrophages drive hepatocyte death-Triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight 2, https://doi.org/10.1172/jci.insight.92902 (2017).
-
(2017)
JCI Insight
, vol.2
-
-
Itoh, M.1
-
32
-
-
85010966335
-
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
-
Schwabl, P. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol 66, 724-733, https://doi.org/10.1016/j.jhep.2016.12.005 (2017).
-
(2017)
J Hepatol
, vol.66
, pp. 724-733
-
-
Schwabl, P.1
-
33
-
-
84901605121
-
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
-
Verbeke, L. et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286-2298, https://doi.org/10.1002/hep.26939 (2014).
-
(2014)
Hepatology
, vol.59
, pp. 2286-2298
-
-
Verbeke, L.1
-
34
-
-
33750628734
-
Expression ofp53, Bax and Bcl-2 proteins in hepatocytes in non-Alcoholic fatty liver disease
-
Panasiuk, A., Dzieciol, J., Panasiuk, B. & Prokopowicz, D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-Alcoholic fatty liver disease. World J Gastroenterol 12, 6198-6202 (2006).
-
(2006)
World J Gastroenterol
, vol.12
, pp. 6198-6202
-
-
Panasiuk, A.1
Dzieciol, J.2
Panasiuk, B.3
Prokopowicz, D.4
-
35
-
-
63049134573
-
Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression
-
Farrell, G. C. et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 24, 443-452, https://doi.org/10.1111/j.1440-1746.2009.05785.x (2009).
-
(2009)
J Gastroenterol Hepatol
, vol.24
, pp. 443-452
-
-
Farrell, G.C.1
-
36
-
-
84862700968
-
Cross-regulation of protein stability by p53 and nuclear receptor SHP
-
Yang, Z., Zhang, Y., Kemper, J. K. & Wang, L. Cross-regulation of protein stability by p53 and nuclear receptor SHP. PLoS One 7, e39789, https://doi.org/10.1371/journal.pone.0039789 (2012).
-
(2012)
PLoS One
, vol.7
, pp. e39789
-
-
Yang, Z.1
Zhang, Y.2
Kemper, J.K.3
Wang, L.4
-
37
-
-
43049163953
-
Acetylation is indispensable for p53 activation
-
Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612-626, https://doi.org/10.1016/j.cell.2008.03.025 (2008).
-
(2008)
Cell
, vol.133
, pp. 612-626
-
-
Tang, Y.1
Zhao, W.2
Chen, Y.3
Zhao, Y.4
Gu, W.5
-
38
-
-
77955418479
-
The C terminus of p53 binds the N-Terminal domain of MDM2
-
Poyurovsky, M. V. et al. The C terminus of p53 binds the N-Terminal domain of MDM2. Nat Struct Mol Biol 17, 982-989, https://doi.org/10.1038/nsmb.1872 (2010).
-
(2010)
Nat Struct Mol Biol
, vol.17
, pp. 982-989
-
-
Poyurovsky, M.V.1
-
39
-
-
84885399978
-
P53 regulates a non-Apoptotic death induced by ROS
-
Montero, J., Dutta, C., van Bodegom, D., Weinstock, D. & Letai, A. p53 regulates a non-Apoptotic death induced by ROS. Cell Death Differ 20, 1465-1474, https://doi.org/10.1038/cdd.2013.52 (2013).
-
(2013)
Cell Death Differ
, vol.20
, pp. 1465-1474
-
-
Montero, J.1
Dutta, C.2
Van Bodegom, D.3
Weinstock, D.4
Letai, A.5
-
40
-
-
84866348839
-
P53/p66Shc-mediated signaling contributes to the progression of non-Alcoholic steatohepatitis in humans and mice
-
Tomita, K. et al. p53/p66Shc-mediated signaling contributes to the progression of non-Alcoholic steatohepatitis in humans and mice. J Hepatol 57, 837-843, https://doi.org/10.1016/j.jhep.2012.05.013 (2012).
-
(2012)
J Hepatol
, vol.57
, pp. 837-843
-
-
Tomita, K.1
-
41
-
-
84922322650
-
Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3
-
Wang, Y. D. et al. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol 29, 322-331, https://doi.org/10.1210/me.2014-1225 (2015).
-
(2015)
Mol Endocrinol
, vol.29
, pp. 322-331
-
-
Wang, Y.D.1
-
42
-
-
85028468258
-
Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
-
Gai, Z. et al. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci Rep 7, 9815, https://doi.org/10.1038/s41598-017-10168-6 (2017).
-
(2017)
Sci Rep
, vol.7
-
-
Gai, Z.1
-
43
-
-
84863502669
-
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
-
Tanaka, N., Matsubara, T., Krausz, K. W., Patterson, A. D. & Gonzalez, F. J. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56, 118-129, https://doi.org/10.1002/hep.25630 (2012).
-
(2012)
Hepatology
, vol.56
, pp. 118-129
-
-
Tanaka, N.1
Matsubara, T.2
Krausz, K.W.3
Patterson, A.D.4
Gonzalez, F.J.5
-
44
-
-
84879888338
-
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
-
Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97-101, https://doi.org/10.1038/nature12347 (2013).
-
(2013)
Nature
, vol.499
, pp. 97-101
-
-
Yoshimoto, S.1
-
45
-
-
84894875873
-
Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice
-
Tomita, K. et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59, 154-169, https://doi.org/10.1002/hep.26604 (2014).
-
(2014)
Hepatology
, vol.59
, pp. 154-169
-
-
Tomita, K.1
-
46
-
-
84942878841
-
New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
-
Beuers, U., Trauner, M., Jansen, P. & Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62, S25-37, https://doi.org/10.1016/j.jhep.2015.02.023 (2015).
-
(2015)
J Hepatol
, vol.62
, pp. S25-37
-
-
Beuers, U.1
Trauner, M.2
Jansen, P.3
Poupon, R.4
-
47
-
-
84864861866
-
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
-
Porez, G., Prawitt, J., Gross, B. & Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53, 1723-1737, https://doi.org/10.1194/jlr.R024794 (2012).
-
(2012)
J Lipid Res
, vol.53
, pp. 1723-1737
-
-
Porez, G.1
Prawitt, J.2
Gross, B.3
Staels, B.4
-
48
-
-
73449124480
-
Mitochondrial glutathione, a key survival antioxidant
-
Mari, M., Morales, A., Colell, A., Garcia-Ruiz, C. & Fernandez-Checa, J. C. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11, 2685-2700, https://doi.org/10.1089/ars.2009.2695 (2009).
-
(2009)
Antioxid Redox Signal
, vol.11
, pp. 2685-2700
-
-
Mari, M.1
Morales, A.2
Colell, A.3
Garcia-Ruiz, C.4
Fernandez-Checa, J.C.5
-
49
-
-
78650953709
-
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
-
Juluri, R. et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol 45, 55-58, https://doi.org/10.1097/MCG.0b013e3181dd1348 (2011).
-
(2011)
J Clin Gastroenterol
, vol.45
, pp. 55-58
-
-
Juluri, R.1
|